Adial Pharmaceuticals (ADIL) Expected to Announce Quarterly Earnings on Wednesday

Adial Pharmaceuticals (NASDAQ:ADIL) is expected to announce its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Adial Pharmaceuticals to post earnings of ($1.0325) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its earnings results on Friday, May 8th. The company reported ($1.48) EPS for the quarter, beating analysts’ consensus estimates of ($2.73) by $1.25.

Adial Pharmaceuticals Stock Performance

Shares of ADIL opened at $3.80 on Wednesday. The company has a 50 day moving average price of $2.72 and a 200-day moving average price of $2.60. Adial Pharmaceuticals has a fifty-two week low of $1.31 and a fifty-two week high of $11.47. The stock has a market capitalization of $8.13 million, a PE ratio of -0.48 and a beta of 1.39.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Needham & Company LLC downgraded Adial Pharmaceuticals to a “buy” rating in a report on Monday, June 15th. Loop Capital set a $6.00 target price on Adial Pharmaceuticals in a research note on Monday, June 15th. Brookline Capital Markets downgraded shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Friday, July 17th. Finally, Alliance Global Partners began coverage on shares of Adial Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $11.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $15.62.

Insider Activity

In other Adial Pharmaceuticals news, major shareholder Coastlands Capital Lp acquired 25,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $65,000.00. Following the acquisition, the insider owned 373,322 shares in the company, valued at approximately $970,637.20. This trade represents a 7.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 36,753 shares of company stock worth $97,638 over the last 90 days. Corporate insiders own 1.86% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ADIL. Jane Street Group LLC raised its stake in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after buying an additional 109,500 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Adial Pharmaceuticals during the third quarter worth about $51,000. Finally, Armistice Capital LLC acquired a new position in shares of Adial Pharmaceuticals during the fourth quarter valued at about $562,000. 16.41% of the stock is owned by institutional investors and hedge funds.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.